Biological Strategies Validation. Western Blot: ABCA1 Antibody [NB400-105] - Western Blot analysis of ABCA1 in total cell lysates of RAW264.9 cells treated with vehicle (-) or 9-cisretinoic acid and 22Rhydroxycholesterol (+). Samples used for this testing were 40 ug of total cell post-nuclear lysate from each group.
Biological Strategies Validation. Western Blot: ABCA1 Antibody [NB400-105] - Detection of ABCA1 in mouse peritoneal macrophages using NB 400-105 (Lot L). ECL exposure, 1 min. Lane 4: T09 uninduced lysate Lane 5: T09 induced lysate.
Immunocytochemistry/Immunofluorescence: ABCA1 Antibody [NB400-105] - Untreated HepG2 cells were grown to 60% confluency, and serum starved for 24 hours prior to being fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-ABCA1 at 5.0ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.
Immunohistochemistry-Paraffin: ABCA1 Antibody [NB400-105] - Detection of ABCA1 in human prostate epithelium showing luminal and membrane staining.
Biological Strategies Validation. Immunocytochemistry/Immunofluorescence: ABCA1 Antibody [NB400-105] - HepG2 cells were grown to 60% confluency, serum starved for 24 hours, and then treated with 1uM TO9 for 24 hours prior to being fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-ABCA1 at 5.0ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.
Flow (Cell Surface): ABCA1 Antibody [NB400-105] - RAW 246.7 cells were either untreated (A) or serum starved for 24 hours, and then treated with 1uM TO9 for 24 hours (B). A surface stain was performed with ABCA1 Antibody NB400-105 (blue) and a matched isotype control NB810-56910 (orange). Cells were incubated in an antibody dilution of 5 ug/mL for 20 minutes at room temperature, followed by Goat Anti-Rabbit Dylight 550-conjugated antibody (SA5-10033, Thermo Fisher).
Western Blot: ABCA1 Antibody [NB400-105] - Analysis of ABCA1, using NB400-105. Samples: 40 ug of total cell post-nuclear lysate of raw macrophages treated with 9-cisretinoic acid and 22R-hydroxycholesterol.
Flow Cytometry: ABCA1 Antibody [NB400-105] - ABCA-1 FITC conjugated antibody of human adipose tissue macrophage subsets by flow cytometry. Image from verified customer review.
Flow Cytometry: ABCA1 Antibody [NB400-105] - ABCA1 antibody was tested at 1: 400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.
ABCA1 (ATP-binding cassette transporter A1), ATP-binding cassette transporter family member, is a cAMP-dependent and sulfonylurea-sensitive anion transporter which is involved in the regulation of apolipoprotein AI (apoAI)-mediated cholesterol efflux from macrophages and act as a key gatekeeper influencing intracellular cholesterol transport. ABCA1 is widely expressed with highest expression levels found in macrophages and is induced by bacterial LPS which regulates its expression through LXR (liver X receptor) -independent mechanism. ABCA1 interacts with MEGF10 and its expression is repressed by ZNF202. ABCA1 phosphorylation at Ser-2054 site regulates the phospholipid efflux and DHHC8 mediated palmitoylation of ABCA1 is essential for its membrane localization. ABCA1 expressed in brain neurons/glia mediates cholesterol transport to apoE which is the major CNS apolipoprotein, and it influences the motor function and synaptic morphology also. Defects in ABCA1 have been linked to HDLD1 (high density lipoprotein deficiency type 1; also known as analphalipoproteinemia, Tangier disease or TGD) and HDLD2 (high density lipoprotein deficiency type 2; also known as familial hypoalphalipoproteinemia or FHA).